New Indication

For adult patients with narcolepsy

WAKIX is now also FDA approved for cataplexy!

Download Clinical Data  >
Online Resources for Healthcare Professionals

Online Resources for Healthcare Professionals

Resource Center

Telemedicine/Symptom Assessment

Telemedicine Guide thumbnail image

Telemedicine Guide

Guidance on conducting telemedicine interactions.

Download

Symptom Assessment Guide thumbnail image

Symptom Assessment Guide

A guide for assessing excessive daytime sleepiness. Contains specific questions that may be particularly helpful for use in telemedicine, as well as guidance for Epworth Sleepiness Scale scoring and interpretation.

Download

EDS Discussion Guide thumbnail image

Excessive Daytime Sleepiness Discussion Guide

Questions to ask your patients with narcolepsy to help identify excessive daytime sleepiness. Contains the Epworth Sleepiness Scale.

Download

Order


Information About WAKIX

WAKIX Mechanism of Action Overview thumbnail image

WAKIX Mechanism of Action Overview

Overview of how histamine works in the brain and its role in promoting wakefulness. Reviews how WAKIX is thought to work.

Download

Order

WAKIX Dosing Overview thumbnail

WAKIX Dosing Overview

Overview of the recommended dosing and titration for WAKIX, as well as setting patient expectations.

Download

Order

Efficacy safety icon

WAKIX Clinical Data Overview

Overview of the data from two clinical studies of WAKIX for the treatment of excessive daytime sleepiness in adults with narcolepsy.

Download

Order


Prescribing WAKIX

WAKIX Prescription Referral Form thumbnail image copy

WAKIX Prescription Referral Form

Downloadable form for writing a WAKIX prescription. Complete and submit the form to WAKIX for You™.

Download

Order

Annotated WAKIX Prescription Referral Form thumbnail image

Guide for Completing the WAKIX Prescription Referral Form

Annotated version of the WAKIX Prescription Referral Form to guide completion and avoid delays in processing.

Download


Patient Education

Patient Brochure thumbnail image

WAKIX Patient Brochure

Resource for patients with information about treatment with WAKIX for the management of excessive daytime sleepiness in adults with narcolepsy.

Download

Order

WAKIX for You flashcard thumbnail image

WAKIX for You Overview Card for Patients

Brief overview of the WAKIX for You patient support program, including contact information.

Download

Order

INDICATIONS AND USAGE & IMPORTANT SAFETY INFORMATION

  • WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.

IMPORTANT SAFETY INFORMATION

Contraindications

  • WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

  • WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
  • The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

  • In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

  • Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
  • Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
  • H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.
  • WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

  • WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.
  • The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
  • WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
  • WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
  • Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

Please see accompanying Full Prescribing Information.

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

CLOSE ×

For adult patients with narcolepsy

WAKIX is now also FDA approved for cataplexy!

Download Clinical Data  >

WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation and in patients with severe hepatic impairment.

CLOSE ×

Watch How WAKIX
Is Thought to Work

Watch Video »

US-WAK-2000132/May 2020

CLOSE ×

Haramandeep Singh, MD
Board-Certified Psychiatrist and Sleep Specialist

Learn About the
Clinical Data for WAKIX

Watch Video »

US-WAK-2000134/Jun 2020